Altogether, these results demonstrated that XQ2B efficiently attenuated systemic inflammation in Trex1-/- mice, highlighting the therapeutic potential of cGAS-specific inhibitors targeting protein-DNA interface in cGAS-related autoimmune diseases. Here, TREX1 is linked to autoimmune disease.